Equities Analysts Issue Forecasts for QNRX Q1 Earnings

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) – Research analysts at Zacks Small Cap issued their Q1 2025 earnings estimates for shares of Quoin Pharmaceuticals in a research report issued on Monday, March 17th. Zacks Small Cap analyst M. Marin anticipates that the company will post earnings of ($0.11) per share for the quarter. The consensus estimate for Quoin Pharmaceuticals’ current full-year earnings is ($2.05) per share. Zacks Small Cap also issued estimates for Quoin Pharmaceuticals’ Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at ($0.12) EPS and Q4 2025 earnings at ($0.11) EPS.

Quoin Pharmaceuticals Price Performance

NASDAQ QNRX opened at $0.30 on Wednesday. Quoin Pharmaceuticals has a one year low of $0.27 and a one year high of $1.57. The business has a 50 day simple moving average of $0.38 and a 200 day simple moving average of $0.55. The stock has a market capitalization of $1.49 million, a P/E ratio of -0.07 and a beta of 1.82.

Quoin Pharmaceuticals (NASDAQ:QNRX) last issued its quarterly earnings results on Thursday, March 13th. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.15.

Hedge Funds Weigh In On Quoin Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the business. Boothbay Fund Management LLC purchased a new stake in shares of Quoin Pharmaceuticals in the fourth quarter worth approximately $53,000. Altium Capital Management LLC purchased a new stake in Quoin Pharmaceuticals in the 4th quarter valued at $184,000. Renaissance Technologies LLC lifted its stake in Quoin Pharmaceuticals by 244.1% during the 4th quarter. Renaissance Technologies LLC now owns 133,122 shares of the company’s stock valued at $87,000 after acquiring an additional 94,431 shares in the last quarter. Finally, Apollon Wealth Management LLC purchased a new position in Quoin Pharmaceuticals during the 4th quarter worth $52,000. Institutional investors own 8.63% of the company’s stock.

Insider Transactions at Quoin Pharmaceuticals

In other news, Director Anthony James Culverwell bought 100,000 shares of the firm’s stock in a transaction that occurred on Monday, December 23rd. The stock was acquired at an average cost of $0.45 per share, with a total value of $45,000.00. Following the transaction, the director now directly owns 100,317 shares of the company’s stock, valued at approximately $45,142.65. This represents a 31,545.74 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Denise P. Carter bought 555,556 shares of the business’s stock in a transaction that occurred on Monday, December 23rd. The stock was purchased at an average price of $0.45 per share, for a total transaction of $250,000.20. Following the completion of the acquisition, the chief operating officer now owns 602,648 shares in the company, valued at $271,191.60. This represents a 1,179.72 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased a total of 777,777 shares of company stock valued at $350,000 in the last quarter. 3.70% of the stock is currently owned by company insiders.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.